Silencing of miR490–3p by H. pylori activates DARPP-32 and induces resistance to gefitinib

Shoumin Zhu,Shayan Khalafi,Zheng Chen,Julio Poveda,Dunfa Peng,Heng Lu,Mohammed Soutto,Jianwen Que,Monica Garcia-Buitrago,Alexander Zaika,Wael El-Rifai
DOI: https://doi.org/10.1016/j.canlet.2020.07.014
IF: 9.756
2020-10-01
Cancer Letters
Abstract:<p>Infection with <em>Helicobacter pylori</em> (<em>H. pylori</em>) is the main risk factor for gastric carcinogenesis. In this study, we investigated the expression, molecular functions, and downstream effectors of miR490–3p in gastric cancer. We used <em>in vitro</em> and <em>in vivo</em> models to investigate <em>H. pylori</em> in regulating miR490–3p and DARPP-32-dependent functions and therapeutic resistance. Human and mouse neoplastic gastric lesions demonstrated a negative correlation between <em>DARPP-32</em> and miR490–3p expression (R = −0.58, <em>P</em> &lt; 0.01). This was also detected following infection with <em>H. pylori</em> (R = −0.66, <em>P</em> &lt; 0.01). Molecular assays confirmed DARPP-32 as a direct target of miR490–3p. <em>CHRM2</em>, the host gene of miR490–3p, was hypermethylated and downregulated in neoplastic gastric tissues (<em>P</em> &lt; 0.05). <em>H. pylori</em> induced methylation and downregulation of <em>CHRM2</em> and miR490–3p. Functionally, the reconstitution of miR490–3p sensitized cancer cells to gefitinib by inactivating DRAPP-32-dependent AKT and STAT3 pathways. Patients with low miR490–3p or high DARPP-32 expression had decreased overall survival (<em>P</em> &lt; 0.05). Hypermethylation-mediated silencing of CHRM2 and miR490–3p by <em>H. pylori</em> increased DARPP-32 expression. Downregulation of miR490–3p in gastric cancer plays a role in gefitinib response by inducing DARPP-32-mediated activation of PI3K/AKT, STAT3 signaling pathways.</p>
oncology
What problem does this paper attempt to address?